Ono S, Tanita T, Hoshikawa Y, Song C, Maeda S, Tabata T, Noda M, Ueda S, Ashino Y, Fujimura S
Department of Thoracic Surgery, Tohoku University, Sendai, Japan.
Nihon Kyobu Shikkan Gakkai Zasshi. 1995 Aug;33(8):862-7.
Prostaglandin E1 (PGE1) has been shown to be a potent pulmonary vasodilator in humans and in many animals. The effects of PGE1 on the development of pulmonary hypertension and on pulmonary vascular remodeling were studied in a rat monocrotaline (MCT) model of human pulmonary hypertension. By 3 weeks after injection, MCT (80 mg/kg S.C.) had resulted in high values of mean pulmonary arterial pressure and of the ratio of right ventricular weight to left ventricle+septum weight (RV/LV+S). PGE1 inhibited the development of pulmonary hypertension (300 micrograms/kg) and right ventricular hypertrophy (300 and 100 micrograms/kg) induced by MCT. Three weeks after the injection, the media walls of pulmonary arteries in lungs from rats given MCT were significantly thicker than those from lungs of control rats. PGE1 (300, 100, and 30 micrograms/kg) resulted in significantly less of this morphologic change, in a dose-dependent manner. These results indicate that PGE1 inhibits the development of pulmonary hypertension associated with lung vascular thickening induced by MCT. PGE1 may be useful for the treatment of pulmonary hypertension in humans.
前列腺素E1（PGE1）已被证明是一种对人类和许多动物有效的肺血管扩张剂。在人类肺动脉高压的大鼠野百合碱（MCT）模型中，研究了PGE1对肺动脉高压发展和肺血管重塑的影响。注射后3周，MCT（80mg/kg皮下注射）导致平均肺动脉压以及右心室重量与左心室+室间隔重量之比（RV/LV+S）升高。PGE1抑制了MCT诱导的肺动脉高压（300μg/kg）和右心室肥大（300和100μg/kg）的发展。注射后3周，给予MCT的大鼠肺中肺动脉的中膜壁明显比对照大鼠肺中的厚。PGE1（300、100和30μg/kg）以剂量依赖的方式导致这种形态学变化明显减轻。这些结果表明，PGE1抑制了与MCT诱导的肺血管增厚相关的肺动脉高压的发展。PGE1可能对治疗人类肺动脉高压有用。
